{"id":"prazosin-hcl","rwe":[],"_fda":{"id":"13018fa7-5e31-ed92-e063-6394a90a4427","set_id":"13018fa7-5e30-ed92-e063-6394a90a4427","openfda":{"unii":["X0Z7454B90"],"route":["ORAL"],"rxcui":["312594"],"spl_id":["13018fa7-5e31-ed92-e063-6394a90a4427"],"brand_name":["Prazosin HCL"],"spl_set_id":["13018fa7-5e30-ed92-e063-6394a90a4427"],"package_ndc":["72189-540-30"],"product_ndc":["72189-540"],"generic_name":["PRAZOSIN HCL"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["PRAZOSIN HYDROCHLORIDE"],"manufacturer_name":["Direct_Rx"],"application_number":["ANDA215697"],"original_packager_product_ndc":["70756-430"]},"version":"1","warnings":["As with all alpha-blockers, prazosin hydrochloride capsules may cause syncope with sudden loss of consciousness. In most cases, this is believed to be due to an excessive postural hypotensive effect, although occasionally the syncopal episode has been preceded by a bout of severe tachycardia with heart rates of 120–160 beats per minute. Syncopal episodes have usually occurred within 30 to 90 minutes of the initial dose of the drug; occasionally, they have been reported in association with rapid dosage increases or the introduction of another antihypertensive drug into the regimen of a patient taking high doses of prazosin hydrochloride capsules. The incidence of syncopal episodes is approximately 1% in patients given an initial dose of 2 mg or greater. Clinical trials conducted during the investigational phase of this drug suggest that syncopal episodes can be minimized by limiting the initial dose of the drug to 1 mg, by subsequently increasing the dosage slowly, and by introducing any additional antihypertensive drugs into the patient's regimen with caution (see DOSAGE AND ADMINISTRATION). Hypotension may develop in patients given prazosin hydrochloride capsules who are also receiving a beta-blocker such as propranolol. If syncope occurs, the patient should be placed in the recumbent position and treated supportively as necessary. This adverse effect is self-limiting and in most cases does not recur after the initial period of therapy or during subsequent dose titration. Patients should always be started on the 1 mg capsules of prazosin hydrochloride capsules. The 2 and 5 mg capsules are not indicated for initial therapy. More common than loss of consciousness are the symptoms often associated with lowering of the blood pressure, namely, dizziness and lightheadedness. The patient should be cautioned about these possible adverse effects and advised what measures to take should they develop. The patient should also be cautioned to avoid situations where injury could result should syncope occur during the initiation of prazosin hydrochloride capsules therapy. Priapism Prolonged erections and priapism have been reported with alpha-1 blockers including prazosin in post marketing experience. In the event of an erection that persists longer than 4 hours, seek immediate medical assistance. If priapism is not treated immediately, penile tissue damage and permanent loss of potency could result."],"overdosage":["Accidental ingestion of at least 50 mg of prazosin hydrochloride capsules in a two year old child resulted in profound drowsiness and depressed reflexes. No decrease in blood pressure was noted. Recovery was uneventful. Should overdosage lead to hypotension, support of the cardiovascular system is of first importance. Restoration of blood pressure and normalization of heart rate may be accomplished by keeping the patient in the supine position. If this measure is inadequate, shock should first be treated with volume expanders. If necessary, vasopressors should then be used. Renal function should be monitored and supported as needed. Laboratory data indicate prazosin hydrochloride capsules are not dialysable because it is protein bound."],"references":["Lubbe, WF, and Hodge, JV: New Zealand Med J, 94 (691) 169–172, 1981. Davey, DA, and Dommisse, J: S.A. Med J, Oct. 4, 1980 (551–556). Manufactured for: Lifestar Pharma LLC 1200 MacArthur Blvd. Mahwah, NJ 07430 USA Made in India Revised: August 2021, V-03"],"description":["Prazosin hydrochloride USP, a quinazoline derivative, is the first of a new chemical class of antihypertensives. It is the hydrochloride salt of 1-(4-amino-6,7-dimethoxy 2-quinazolinyl)-4-(2-furoyl) piperazine and its structural formula is: [Chemical Structure] Molecular Formula: C19H21N5O4•HCl It is white to tan powder, slightly soluble in water, in methanol, in dimethyl formamide, in dimethyl acetamide, very slightly soluble in alcohol, practically insoluble in isotonic saline, in chloroform and in acetone and has a molecular weight of 419.86. Each capsule, for oral administration, contains prazosin hydrochloride, USP equivalent (as the polyhydrate) to 1 mg, 2 mg or 5 mg of prazosin. Inert ingredients in the formulations are: colloidal silicon dioxide, lactose monohydrate, magnesium stearate, microcrystalline cellulose and sodium lauryl sulfate. The hard gelatin capsules contain gelatin and titanium dioxide. In addition, the 2 mg empty gelatin capsules contain FD&C Red No. 40, FD&C Red No. 3 and FD&C Blue No. 1; and the 5 mg empty gelatin capsules contain FD&C Red 3 and FD&C Blue No. 1. The imprinting ink also contains Black Iron Oxide, Potassium Hydroxide, Shellac. FDA approved dissolution test specifications differ from USP."],"precautions":["General Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract surgery in some patients treated with alpha-1 blockers. This variant of small pupil syndrome is characterized by the combination of a flaccid iris that billows in response to intraoperative irrigation currents, progressive intraoperative miosis despite preoperative dilation with standard mydriatic drugs, and potential prolapse of the iris toward the phacoemulsification incisions. The patient's ophthalmologist should be prepared for possible modifications to the surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances. There does not appear to be a benefit of stopping alpha-1 blocker therapy prior to cataract surgery. Information for Patients Dizziness or drowsiness may occur after the first dose of this medicine. Avoid driving or performing hazardous tasks for the first 24 hours after taking this medicine or when the dose is increased. Dizziness, lightheadedness, or fainting may occur, especially when rising from a lying or sitting position. Getting up slowly may help lessen the problem. These effects may also occur if you drink alcohol, stand for long periods of time, exercise, or if the weather is hot. While taking prazosin hydrochloride capsules, be careful in the amount of alcohol you drink. Also, use extra care during exercise or hot weather, or if standing for long periods. Check with your physician if you have any questions. Drug Interactions Prazosin hydrochloride capsules has been administered without any adverse drug interaction in limited clinical experience to date with the following: (1) cardiac glycosides– digitalis and digoxin; (2) hypoglycemics–insulin, chlorpropamide, phenformin, tolazamide, and tolbutamide; (3) tranquilizers and sedatives–chlordiazepoxide, diazepam, and phenobarbital; (4) antigout– allopurinol, colchicine, and probenecid; (5) antiarrhythmics–procainamide, propranolol (see WARNINGS however), and quinidine; and (6) analgesics, antipyretics and anti-inflammatories– propoxyphene, aspirin, indomethacin, and phenylbutazone. Addition of a diuretic or other antihypertensive agent to prazosin hydrochloride capsules has been shown to cause an additive hypotensive effect. This effect can be minimized by reducing the prazosin hydrochloride capsules dose to 1 to 2 mg three times a day, by introducing additional antihypertensive drugs cautiously, and then by retitrating prazosin hydrochloride capsules based on clinical response. Concomitant administration of prazosin hydrochloride capsules with a phosphodiesterase-5 (PDE-5) inhibitor can result in additive blood pressure lowering effects and symptomatic hypotension (see DOSAGE AND ADMINISTRATION). Drug/Laboratory Test Interactions In a study on five patients given from 12 to 24 mg of prazosin per day for 10 to 14 days, there was an average increase of 42% in the urinary metabolite of norepinephrine and an average increase in urinary VMA of 17%. Therefore, false positive results may occur in screening tests for pheochromocytoma in patients who are being treated with prazosin. If an elevated VMA is found, prazosin should be discontinued and the patient retested after a month. Laboratory Tests In clinical studies in which lipid profiles were followed, there were generally no adverse changes noted between pre-and post-treatment lipid levels. Carcinogenesis, Mutagenesis, Impairment of Fertility: No carcinogenic potential was demonstrated in an 18 month study in rats with prazosin hydrochloride capsules at dose levels more than 225 times the usual maximum recommended human dose of 20 mg per day. Prazosin hydrochloride capsules was not mutagenic in in vivo genetic toxicology studies. In a fertility and general reproductive performance study in rats, both males and females, treated with 75 mg/kg (225 times the usual maximum recommended human dose), demonstrated decreased fertility, while those treated with 25 mg/kg (75 times the usual maximum recommended human dose) did not. In chronic studies (one year or more) of prazosin hydrochloride capsules in rats and dogs, testicular changes consisting of atrophy and necrosis occurred at 25 mg/kg/day (75 times the usual maximum recommended human dose). No testicular changes were seen in rats or dogs at 10 mg/kg/day (30 times the usual maximum recommended human dose). In view of the testicular changes observed in animals, 105 patients on long term prazosin hydrochloride capsules therapy were monitored for 17-ketosteroid excretion and no changes indicating a drug effect were observed. In addition, 27 males on prazosin hydrochloride capsules for up to 51 months did not have changes in sperm morphology suggestive of drug effect. Usage in Pregnancy: Prazosin hydrochloride capsules has been shown to be associated with decreased litter size at birth, 1, 4, and 21 days of age in rats when given doses more than 225 times the usual maximum recommended human dose. No evidence of drug-related external, visceral, or skeletal fetal abnormalities were observed. No drug-related external, visceral, or skeletal abnormalities were observed in fetuses of pregnant rabbits and pregnant monkeys at doses more than 225 times and 12 times the usual maximum recommended human dose, respectively. The use of prazosin and a beta-blocker for the control of severe hypertension in 44 pregnant women revealed no drug-related fetal abnormalities or adverse effects. Therapy with prazosin was continued for as long as 14 weeks.1 Prazosin has also been used alone or in combination with other hypotensive agents in severe hypertension of pregnancy by other investigators. No fetal or neonatal abnormalities have been reported with the use of prazosin.2 There are no adequate and well controlled studies which establish the safety of Prazosin hydrochloride capsules in pregnant women. Prazosin hydrochloride capsules should be used during pregnancy only if the potential benefit justifies the potential risk to the mother and fetus. Nursing Mothers: Prazosin hydrochloride has been shown to be excreted in small amounts in human milk. Caution should be exercised when prazosin hydrochloride capsule are administered to a nursing woman. Usage in Children: Safety and effectiveness in children have not been established."],"how_supplied":["Prazosin Hydrochloride Capsules, USP are available containing prazosin hydrochloride, USP equivalent to 1 mg, 2 mg, or 5 mg of prazosin. The 1 mg capsule is White opaque cap/ white opaque body, hard gelatin capsule imprinted with [Image] on cap and \"429\" on body with black ink containing white to off white powder. They are available as follows: NDC 70756-429-11 bottles of 100 capsules. This package is child resistant NDC 70756-429-12 bottles of 1000 capsules. This package is not child resistant The 2 mg capsule is Pink opaque cap/ Pink opaque body, hard gelatin capsule imprinted with [Image] on cap and \"430\" on body with black ink containing white to off white powder. They are available as follows: NDC 72189-540-30 bottles of 30 capsules. This package is child resistant NDC 70756-430-12 bottles of 1000 capsules. This package is not child resistant The 5 mg capsule is Blue opaque cap/ Blue opaque body, hard gelatin capsule imprinted with [Image] on cap and \"440\" on body with black ink containing white to off white powder. They are available as follows: NDC 70756-440-11 bottles of 100 capsules. This package is child resistant NDC 70756-440-12 bottles of 1000 capsules. This package is not child resistant"],"effective_time":"20240306","adverse_reactions":["Clinical trials were conducted on more than 900 patients. During these trials and subsequent marketing experience, the most frequent reactions associated with prazosin hydrochloride capsules therapy are: dizziness 10.3%, headache 7.8%, drowsiness 7.6%, lack of energy 6.9%, weakness 6.5%, palpitations 5.3%, and nausea 4.9%. In most instances, side effects have disappeared with continued therapy or have been tolerated with no decrease in dose of drug. Less frequent adverse reactions which are reported to occur in 1–4% of patients are: Gastrointestinal: vomiting, diarrhea, constipation. Cardiovascular: edema, orthostatic hypotension, dyspnea, syncope. Central Nervous System: vertigo, depression, nervousness. Dermatologic: rash. Genitourinary: urinary frequency. EENT: blurred vision, reddened sclera, epistaxis, dry mouth, nasal congestion. In addition, fewer than 1% of patients have reported the following (in some instances, exact causal relationships have not been established): Gastrointestinal: abdominal discomfort and/or pain, liver function abnormalities, pancreatitis. Cardiovascular: tachycardia. Central Nervous System: paresthesia, hallucinations. Dermatologic: pruritus, alopecia, lichen planus. Genitourinary: incontinence, impotence, priapism. EENT: tinnitus. Other: diaphoresis, fever, positive ANA titer, arthralgia. Single reports of pigmentary mottling and serous retinopathy, and a few reports of cataract development or disappearance have been reported. In these instances, the exact causal relationship has not been established because the baseline observations were frequently inadequate. In more specific slit-lamp and funduscopic studies, which included adequate baseline examinations, no drug-related abnormal ophthalmological findings have been reported. Literature reports exist associating prazosin hydrochloride capsules therapy with a worsening of pre-existing narcolepsy. A causal relationship is uncertain in these cases. In post-marketing experience, the following adverse events have been reported: Autonomic Nervous System: flushing. Body As A Whole: allergic reaction, asthenia, malaise, pain. Cardiovascular, General: angina pectoris, hypotension. Endocrine: gynecomastia. Heart Rate/Rhythm: bradycardia. Psychiatric: insomnia. Skin/Appendages: urticaria. Vascular (Extracardiac): vasculitis. Vision: eye pain. Special Senses: During cataract surgery, a variant of small pupil syndrome known as Intraoperative Floppy Iris Syndrome (IFIS) has been reported in association with alpha-1 blocker therapy (see PRECAUTIONS). To report SUSPECTED ADVERSE REACTIONS, contact Lifestar Pharma LLC at 1-888-995-4337 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."],"contraindications":["Prazosin hydrochloride capsules are contraindicated in patients with known sensitivity to quinazolines, prazosin, or any of the inert ingredients."],"storage_and_handling":["Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from light. Dispense in a tight, light-resistant container as defined in the USP Keep this and all medication out of the reach of children."],"clinical_pharmacology":["The exact mechanism of the hypotensive action of prazosin is unknown. Prazosin causes a decrease in total peripheral resistance and was originally thought to have a direct relaxant action on vascular smooth muscle. Recent animal studies, however, have suggested that the vasodilator effect of prazosin is also related to blockade of postsynaptic alpha-adrenoceptors. The results of dog forelimb experiments demonstrate that the peripheral vasodilator effect of prazosin is confined mainly to the level of the resistance vessels (arterioles). Unlike conventional alpha-blockers, the antihypertensive action of prazosin is usually not accompanied by a reflex tachycardia. Tolerance has not been observed to develop in long term therapy. Hemodynamic studies have been carried out in man following acute single dose administration and during the course of long term maintenance therapy. The results confirm that the therapeutic effect is a fall in blood pressure unaccompanied by a clinically significant change in cardiac output, heart rate, renal blood flow and glomerular filtration rate. There is no measurable negative chronotropic effect. In clinical studies to date, prazosin hydrochloride has not increased plasma renin activity. In man, blood pressure is lowered in both the supine and standing positions. This effect is most pronounced on the diastolic blood pressure. Following oral administration, human plasma concentrations reach a peak at about three hours with a plasma half-life of two to three hours. The drug is highly bound to plasma protein. Bioavailability studies have demonstrated that the total absorption relative to the drug in a 20% alcoholic solution is 90%, resulting in peak levels approximately 65% of that of the drug in solution. Animal studies indicate that prazosin hydrochloride is extensively metabolized, primarily by demethylation and conjugation, and excreted mainly via bile and feces. Less extensive human studies suggest similar metabolism and excretion in man. In clinical studies in which lipid profiles were followed, there were generally no adverse changes noted between pre-and post-treatment lipid levels."],"indications_and_usage":["Prazosin hydrochloride capsules are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Prazosin hydrochloride capsules can be used alone or in combination with other antihypertensive drugs such as diuretics or beta-adrenergic blocking agents."],"spl_unclassified_section":["For Oral Use Rx Only"],"dosage_and_administration":["The dose of prazosin hydrochloride capsules should be adjusted according to the patient's individual blood pressure response. The following is a guide to its administration: Initial Dose 1 mg two or three times a day (see WARNINGS.) Maintenance Dose Dosage may be slowly increased to a total daily dose of 20 mg given in divided doses. The therapeutic dosages most commonly employed have ranged from 6 mg to 15 mg daily given in divided doses. Doses higher than 20 mg usually do not increase efficacy, however a few patients may benefit from further increases up to a daily dose of 40 mg given in divided doses. After initial titration some patients can be maintained adequately on a twice daily dosage regimen. Use With Other Drugs When adding a diuretic or other antihypertensive agent, the dose of prazosin hydrochloride capsules should be reduced to 1 mg or 2 mg three times a day and retitration then carried out. Concomitant administration of prazosin hydrochloride capsules with a PDE-5 inhibitor can result in additive blood pressure lowering effects and symptomatic hypotension; therefore, PDE-5 inhibitor therapy should be initiated at the lowest dose in patients taking prazosin hydrochloride capsules."],"spl_product_data_elements":["Prazosin HCL Prazosin HCL TITANIUM DIOXIDE FD&C RED NO. 40 PRAZOSIN HYDROCHLORIDE PRAZOSIN CELLULOSE, MICROCRYSTALLINE FD&C RED NO. 3 LACTOSE MONOHYDRATE FERROSOFERRIC OXIDE MAGNESIUM STEARATE POTASSIUM HYDROXIDE SILICON DIOXIDE SODIUM LAURYL SULFATE FD&C BLUE NO. 1 GELATIN SHELLAC Lifestar;430"],"package_label_principal_display_panel":["72189-0540-30"]},"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"Reported 56 times"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"Reported 50 times"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"Reported 47 times"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"Reported 45 times"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"Reported 43 times"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"Reported 43 times"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"Reported 42 times"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"Reported 42 times"},{"date":"","signal":"HYPOTENSION","source":"FDA FAERS","actionTaken":"Reported 40 times"},{"date":"","signal":"ANXIETY","source":"FDA FAERS","actionTaken":"Reported 38 times"}],"drugInteractions":[{"name":"P-glycoprotein Substrates","source":"DrugCentral","severity":"Potentially significant","description":"P-glycoprotein Inducers - P-glycoprotein Substrates"},{"name":"sildenafil","source":"DrugCentral","severity":"Significant","description":"PRAZOSIN/SILDENAFIL CITRATE [VA Drug Interaction]"},{"name":"tadalafil","source":"DrugCentral","severity":"Significant","description":"PRAZOSIN/TADALAFIL [VA Drug Interaction]"}],"commonSideEffects":[{"effect":"dizziness","drugRate":"10.3%","severity":"mild","_validated":true},{"effect":"headache","drugRate":"7.8%","severity":"mild","_validated":true},{"effect":"drowsiness","drugRate":"7.6%","severity":"mild","_validated":true},{"effect":"lack of energy","drugRate":"6.9%","severity":"mild","_validated":true},{"effect":"weakness","drugRate":"6.5%","severity":"mild","_validated":true},{"effect":"palpitations","drugRate":"5.3%","severity":"mild","_validated":true},{"effect":"nausea","drugRate":"4.9%","severity":"mild","_validated":true},{"effect":"vomiting","drugRate":"1-4%","severity":"mild","_validated":true},{"effect":"diarrhea","drugRate":"1-4%","severity":"mild","_validated":true},{"effect":"constipation","drugRate":"1-4%","severity":"mild","_validated":true},{"effect":"edema","drugRate":"1-4%","severity":"mild","_validated":true},{"effect":"orthostatic hypotension","drugRate":"1-4%","severity":"mild","_validated":true},{"effect":"dyspnea","drugRate":"1-4%","severity":"mild","_validated":true},{"effect":"syncope","drugRate":"1-4%","severity":"serious","_validated":true},{"effect":"vertigo","drugRate":"1-4%","severity":"mild","_validated":true},{"effect":"depression","drugRate":"1-4%","severity":"serious","_validated":true},{"effect":"nervousness","drugRate":"1-4%","severity":"mild","_validated":true},{"effect":"rash","drugRate":"1-4%","severity":"mild","_validated":true},{"effect":"urinary frequency","drugRate":"1-4%","severity":"mild","_validated":true},{"effect":"blurred vision","drugRate":"1-4%","severity":"mild","_validated":true},{"effect":"reddened sclera","drugRate":"1-4%","severity":"mild","_validated":true},{"effect":"epistaxis","drugRate":"1-4%","severity":"mild","_validated":true},{"effect":"dry mouth","drugRate":"1-4%","severity":"mild","_validated":true},{"effect":"nasal congestion","drugRate":"1-4%","severity":"mild","_validated":true},{"effect":"abdominal discomfort and/or pain","drugRate":"<1%","severity":"mild","_validated":true},{"effect":"liver function abnormalities","drugRate":"<1%","severity":"serious","_validated":true},{"effect":"pancreatitis","drugRate":"<1%","severity":"serious","_validated":true},{"effect":"tachycardia","drugRate":"<1%","severity":"mild","_validated":true},{"effect":"paresthesia","drugRate":"<1%","severity":"mild","_validated":true},{"effect":"hallucinations","drugRate":"<1%","severity":"serious","_validated":true},{"effect":"pruritus","drugRate":"<1%","severity":"mild","_validated":true},{"effect":"alopecia","drugRate":"<1%","severity":"mild","_validated":true},{"effect":"lichen planus","drugRate":"<1%","severity":"mild","_validated":true},{"effect":"incontinence","drugRate":"<1%","severity":"mild","_validated":true},{"effect":"impotence","drugRate":"<1%","severity":"mild","_validated":true},{"effect":"priapism","drugRate":"<1%","severity":"serious","_validated":true},{"effect":"tinnitus","drugRate":"<1%","severity":"mild","_validated":true},{"effect":"diaphoresis","drugRate":"<1%","severity":"mild","_validated":true},{"effect":"fever","drugRate":"<1%","severity":"mild","_validated":true},{"effect":"positive ANA titer","drugRate":"<1%","severity":"mild","_validated":true},{"effect":"arthralgia","drugRate":"<1%","severity":"mild","_validated":true},{"effect":"allergic reaction","drugRate":"<1%","severity":"serious","_validated":true},{"effect":"asthenia","drugRate":"<1%","severity":"mild","_validated":true},{"effect":"malaise","drugRate":"<1%","severity":"mild","_validated":true},{"effect":"pain","drugRate":"<1%","severity":"mild","_validated":true},{"effect":"angina pectoris","drugRate":"<1%","severity":"serious","_validated":true},{"effect":"hypotension","drugRate":"<1%","severity":"serious","_validated":true},{"effect":"gynecomastia","drugRate":"<1%","severity":"mild","_validated":true},{"effect":"bradycardia","drugRate":"<1%","severity":"mild","_validated":true},{"effect":"insomnia","drugRate":"<1%","severity":"mild","_validated":true},{"effect":"urticaria","drugRate":"<1%","severity":"mild","_validated":true},{"effect":"vasculitis","drugRate":"<1%","severity":"serious","_validated":true},{"effect":"eye pain","drugRate":"<1%","severity":"mild","_validated":true},{"effect":"Intraoperative Floppy Iris Syndrome (IFIS)","drugRate":"<1%","severity":"serious","_validated":true}],"contraindications":["Cataract surgery","End stage renal disease","Intraoperative floppy iris syndrome","Micturition syncope","Narcolepsy","Syncope"],"specialPopulations":{"Pregnancy":"This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus. AU TGA pregnancy category: B2US FDA pregnancy category: C Animal studies have revealed decreased litter size in rats at doses greater than 225 times the usual maximum recommended human dose. In humans, use of this drug alone or with other hypotensive agents for severe hypertension in pregnant women failed to reveal fetal or neonatal abnormalities or adverse effects. There are no controlled data in human pregnancy. AU TGA pregnancy category B2: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals are inadequate or may be lacking, but available data show no evidence of an increased occurrence of fetal damage.US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.","Geriatric use":"text","Paediatric use":"text","Renal impairment":"text","Hepatic impairment":"text"}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_recalls":[{"date":"20150429","reason":"Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.","classification":"Class II"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=prazosin-hcl","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:53:59.188883+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:54:06.126156+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:53:59.206960+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=prazosin-hcl","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:54:07.427412+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:53:56.958295+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:53:56.958367+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Adrenergic receptor alpha-1 antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:54:08.380794+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1558/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:54:08.248909+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA215697","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:53:56.958379+00:00"}},"allNames":"prazosin hcl","offLabel":[],"synonyms":["prazosin","prazosin hydrochloride","furazosin","prazosin HCl"],"timeline":[],"_dailymed":{"setId":"fb6db16d-3768-631b-e053-6294a90a1cee","title":"PRAZOSIN HCL CAPSULE [DIRECT_RX]","labeler":""},"aiSummary":"Prazosin Hcl is a small molecule that acts as an adrenergic receptor alpha-1 antagonist. It has been studied in clinical trials for various conditions, including Alcohol Use Disorder, Posttraumatic Stress Disorder (PTSD), Essential Hypertension, Cardiovascular Disease, and Stroke.","brandName":"Prazosin Hcl","ecosystem":[],"isGeneric":true,"mechanism":{"target":"5-hydroxytryptamine receptor 1D","novelty":"me-too","targets":[{"gene":"HTR1D","source":"DrugCentral","target":"5-hydroxytryptamine receptor 1D","protein":"5-hydroxytryptamine receptor 1D","activityType":"Ki"},{"gene":"HTR2A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2A","protein":"5-hydroxytryptamine receptor 2A","activityType":"Ki"},{"gene":"HTR2B","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2B","protein":"5-hydroxytryptamine receptor 2B","activityType":"Ki"},{"gene":"ADORA3","source":"DrugCentral","target":"Adenosine receptor A3","protein":"Adenosine receptor A3","activityType":"IC50"},{"gene":"ADRA1A","source":"DrugCentral","target":"Alpha-1A adrenergic receptor","protein":"Alpha-1A adrenergic receptor","activityType":"Ki"},{"gene":"ADRA1B","source":"DrugCentral","target":"Alpha-1B adrenergic receptor","protein":"Alpha-1B adrenergic receptor","activityType":"Ki"},{"gene":"ADRA1D","source":"DrugCentral","target":"Alpha-1D adrenergic receptor","protein":"Alpha-1D adrenergic receptor","activityType":"Ki"},{"gene":"ADRA2A","source":"DrugCentral","target":"Alpha-2A adrenergic receptor","protein":"Alpha-2A adrenergic receptor","activityType":"Ki"},{"gene":"ADRA2B","source":"DrugCentral","target":"Alpha-2B adrenergic receptor","protein":"Alpha-2B adrenergic receptor","activityType":"Ki"},{"gene":"ADRA2C","source":"DrugCentral","target":"Alpha-2C adrenergic receptor","protein":"Alpha-2C adrenergic receptor","activityType":"Ki"}],"modality":"small molecule","drugClass":"prazosin","explanation":"","oneSentence":"","technicalDetail":"Prazosin HCl is a selective alpha-1 adrenergic receptor antagonist that works by competing with norepinephrine for binding sites on the receptor. This competition prevents the receptor from being activated, resulting in vasodilation and a decrease in blood pressure. Prazosin HCl has a rapid onset of action and is effective in reducing blood pressure in patients with hypertension."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"yoyGrowth":"7%","launchDate":"1976","annualCostUS":"$13,980.00","_launchSource":"DrugCentral (FDA 1976-06-23, PFIZER)","genericStatus":"Generic — off-patent","currentRevenue":"","peakSalesEstimate":""},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4209","fields":["approvals","synonyms","ATC","pharmacokinetics","patents","indications","contraindications","interactions","targets"],"source":"DrugCentral"},{"id":2,"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=prazosin-hcl","fields":["mechanism","safety","indications","administration"],"source":"FDA Drug Label (DailyMed)"},{"id":3,"url":"https://clinicaltrials.gov/search?intr=prazosin-hcl","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":4,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=prazosin-hcl","fields":["publications"],"source":"PubMed/NCBI"},{"id":5,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":6,"url":"https://open.fda.gov/apis/drug/event/","fields":["safetySignals"],"source":"FDA FAERS"},{"id":7,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":8,"url":"https://www.whocc.no/atc_ddd_index/","fields":["classification"],"source":"WHO ATC/DDD Index"},{"id":9,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:54:13.010287+00:00","fieldsConflicting":1,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Lamotrigine","company":"Unknown","advantage":"Treats Post Traumatic Stress Disorder"},{"name":"Quetiapine","company":"Unknown","advantage":"Treats Post Traumatic Stress Disorder"},{"name":"Mirtazapine","company":"Unknown","advantage":"Treats Post Traumatic Stress Disorder"},{"name":"Amitriptyline","company":"Unknown","advantage":"Treats Post Traumatic Stress Disorder"},{"name":"Venlafaxine","company":"Unknown","advantage":"Treats Post Traumatic Stress Disorder"},{"name":"Aripiprazole","company":"Unknown","advantage":"Treats Post Traumatic Stress Disorder"},{"name":"Sertraline","company":"Unknown","advantage":"Less potential for drowsiness than many other antidepressants"}],"genericName":"prazosin-hcl","indications":{"approved":[{"name":"Hypertension","regulator":"FDA"},{"name":"Lowering blood pressure","regulator":"FDA"},{"name":"Reducing the risk of fatal and nonfatal cardiovascular events","regulator":"FDA"},{"name":"Reducing the risk of stroke","regulator":"FDA"},{"name":"Reducing the risk of myocardial infarctions","regulator":"FDA"},{"name":"Reducing cardiovascular mortality","regulator":"FDA"}],"offLabel":[{"name":"Benign prostatic hyperplasia","source":"DrugCentral"},{"name":"Chronic Post Traumatic Stress Disorder with Trauma-related Nightmares","source":"DrugCentral"},{"name":"PTSD related nightmares","source":"DrugCentral"}]},"_drugCentral":{"patents":[],"targets":[{"gene":"HTR1D","target":"5-hydroxytryptamine receptor 1D","protein":"5-hydroxytryptamine receptor 1D","activityType":"Ki","activityUnit":"","activityValue":9.48},{"gene":"HTR2A","target":"5-hydroxytryptamine receptor 2A","protein":"5-hydroxytryptamine receptor 2A","activityType":"Ki","activityUnit":"","activityValue":7.73},{"gene":"HTR2B","target":"5-hydroxytryptamine receptor 2B","protein":"5-hydroxytryptamine receptor 2B","activityType":"Ki","activityUnit":"","activityValue":5.582},{"gene":"ADORA3","target":"Adenosine receptor A3","protein":"Adenosine receptor A3","activityType":"IC50","activityUnit":"","activityValue":9.07},{"gene":"ADRA1A","target":"Alpha-1A adrenergic receptor","protein":"Alpha-1A adrenergic receptor","activityType":"Ki","activityUnit":"","activityValue":10.4},{"gene":"ADRA1B","target":"Alpha-1B adrenergic receptor","protein":"Alpha-1B adrenergic receptor","activityType":"Ki","activityUnit":"","activityValue":9.68},{"gene":"ADRA1D","target":"Alpha-1D adrenergic receptor","protein":"Alpha-1D adrenergic receptor","activityType":"Ki","activityUnit":"","activityValue":9.7},{"gene":"ADRA2A","target":"Alpha-2A adrenergic receptor","protein":"Alpha-2A adrenergic receptor","activityType":"Ki","activityUnit":"","activityValue":6.68},{"gene":"ADRA2B","target":"Alpha-2B adrenergic receptor","protein":"Alpha-2B adrenergic receptor","activityType":"Ki","activityUnit":"","activityValue":7.89},{"gene":"ADRA2C","target":"Alpha-2C adrenergic receptor","protein":"Alpha-2C adrenergic receptor","activityType":"Ki","activityUnit":"","activityValue":7.62},{"gene":"DRD4","target":"D(4) dopamine receptor","protein":"D(4) dopamine receptor","activityType":"Ki","activityUnit":"","activityValue":5.08},{"gene":"MMP1","target":"Interstitial collagenase","protein":"Interstitial collagenase","activityType":"IC50","activityUnit":"","activityValue":5.394},{"gene":"MMP9","target":"Matrix metalloproteinase-9","protein":"Matrix metalloproteinase-9","activityType":"IC50","activityUnit":"","activityValue":5.157},{"gene":"SLC47A1","target":"Multidrug and toxin extrusion protein 1","protein":"Multidrug and toxin extrusion protein 1","activityType":"IC50","activityUnit":"","activityValue":5.8},{"gene":"SLC47A2","target":"Multidrug and toxin extrusion protein 2","protein":"Multidrug and toxin extrusion protein 2","activityType":"IC50","activityUnit":"","activityValue":4.42},{"gene":"KCNH2","target":"Potassium voltage-gated channel subfamily H member 2","protein":"Potassium voltage-gated channel subfamily H member 2","activityType":"IC50","activityUnit":"","activityValue":5.8},{"gene":"NQO2","target":"Ribosyldihydronicotinamide dehydrogenase [quinone]","protein":"Ribosyldihydronicotinamide dehydrogenase [quinone]","activityType":"IC50","activityUnit":"","activityValue":8.11},{"gene":"SCN1A","target":"Sodium channel alpha subunits; brain (Types I, II, III)","protein":"Sodium channel protein type 1 subunit alpha","activityType":"IC50","activityUnit":"","activityValue":5},{"gene":"SCN2A","target":"Sodium channel alpha subunits; brain (Types I, II, III)","protein":"Sodium channel protein type 2 subunit alpha","activityType":"IC50","activityUnit":"","activityValue":5},{"gene":"SCN3A","target":"Sodium channel alpha subunits; brain (Types I, II, III)","protein":"Sodium channel protein type 3 subunit alpha","activityType":"IC50","activityUnit":"","activityValue":5}],"atcCodes":["C02CA01","C02LE01"],"synonyms":["prazosin","prazosin hydrochloride","furazosin","prazosin HCl"],"approvals":[{"date":"1976-06-23","orphan":false,"company":"PFIZER","regulator":"FDA"}],"properties":{"S":{"name":"Water solubility","units":"mg/mL","value":1.4},"BA":{"name":"Bioavailability","units":"%","value":68},"CL":{"name":"Clearance","units":"mL/min/kg","value":4.7},"Vd":{"name":"Volume of distribution","units":"L/kg","value":0.73},"fu":{"name":"Fraction unbound in plasma","units":"%","value":0.06},"EoM":{"name":"Fraction excreted unchanged in urine","units":"%","value":0.5},"MRTD":{"name":"Maximum Recommended Therapeutic Daily Dose","units":"µM/kg/day","value":1.49000001},"BDDCS":{"name":"Biopharmaceutical Drug Disposition Classification System","units":"","value":1},"t_half":{"name":"Half-life","units":"hours","value":2}},"drugClasses":["prazosin","P-glycoprotein Inducers"],"identifiers":{"NUI":"N0000147986","MMSL":"2426","NDDF":"000635","UNII":"XM03YJ541D","VUID":"4019901","CHEBI":"CHEBI:8364","VANDF":"4018850","INN_ID":"2593","RXNORM":"203210","UMLSCUI":"C0032912","ChEMBL_ID":"CHEMBL2","KEGG_DRUG":"D00609","DRUGBANK_ID":"DB00457","PDB_CHEM_ID":" XRA","PUBCHEM_CID":"4893","SNOMEDCT_US":"387283005","IUPHAR_LIGAND_ID":"503","SECONDARY_CAS_RN":"19237-84-4","MESH_DESCRIPTOR_UI":"D011224"},"indications":[{"name":"Hypertensive disorder","source":"DrugCentral","umlsCui":"C0020538","snomedId":38341003}],"formulations":[{"form":"CAPSULE","route":"ORAL","status":"ANDA","tradeName":"PRAZOSIN HYDROCHLORIDE"},{"form":"CAPSULE","route":"ORAL","status":"ANDA","tradeName":"Prazosin HCL"},{"form":"CAPSULE","route":"ORAL","status":"ANDA","tradeName":"Prazosin Hydrochloride"},{"form":"CAPSULE","route":"ORAL","status":"ANDA","tradeName":"Prazosin hydrochloride"},{"form":"CAPSULE","route":"ORAL","status":"ANDA","tradeName":"prazosin hydrochloride"},{"form":"CAPSULE","route":"ORAL","status":"NDA","tradeName":"Minipress"},{"form":"CAPSULE","route":"ORAL","status":"NDA AUTHORIZED GENERIC","tradeName":"Prazosin Hydrochloride"},{"form":"CAPSULE","route":"ORAL","status":"NDA authorized generic","tradeName":"Prazosin"},{"form":"CAPSULE","route":"ORAL","status":"NDA authorized generic","tradeName":"Prazosin Hydrochloride"}],"offLabelUses":[{"name":"Benign prostatic hyperplasia","source":"DrugCentral","umlsCui":"C1739363","snomedId":266569009},{"name":"Chronic Post Traumatic Stress Disorder with Trauma-related Nightmares","source":"DrugCentral","umlsCui":"","snomedId":""},{"name":"PTSD related nightmares","source":"DrugCentral","umlsCui":"C1997862","snomedId":428687006}],"drugCentralId":4209,"drugInteractions":[{"risk":"Potentially significant","description":"P-glycoprotein Inducers - P-glycoprotein Substrates","interactingClass":"P-glycoprotein Substrates"},{"risk":"Significant","description":"PRAZOSIN/SILDENAFIL CITRATE [VA Drug Interaction]","interactingClass":"sildenafil"},{"risk":"Significant","description":"PRAZOSIN/TADALAFIL [VA Drug Interaction]","interactingClass":"tadalafil"}],"contraindications":[{"name":"Cataract surgery","source":"DrugCentral","umlsCui":"C2939459","snomedId":110473004},{"name":"End stage renal disease","source":"DrugCentral","umlsCui":"C0022661","snomedId":46177005},{"name":"Intraoperative floppy iris syndrome","source":"DrugCentral","umlsCui":"C1688637","snomedId":418801006},{"name":"Micturition syncope","source":"DrugCentral","umlsCui":"C0340855","snomedId":234168001},{"name":"Narcolepsy","source":"DrugCentral","umlsCui":"C0027404","snomedId":60380001},{"name":"Syncope","source":"DrugCentral","umlsCui":"C0039070","snomedId":271594007}]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04135846","phase":"PHASE2","title":"Alpha-1 Blockade for Alcohol Use Disorder (AUD)","status":"RECRUITING","sponsor":"Brown University","startDate":"2019-12-19","conditions":"Alcohol Use Disorder (AUD)","enrollment":184},{"nctId":"NCT07231978","phase":"PHASE1","title":"A Study to Learn How Different Forms of the Study Medicine Called Prazosin Are Taken up Into the Blood in Healthy Adults","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-11-14","conditions":"Healthy","enrollment":72},{"nctId":"NCT06629077","phase":"PHASE2","title":"Brain Blood Vessel Responses to Changes in Blood Flow","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2026-02-26","conditions":"Magnetic Resonance Imaging, Cerebrovascular Circulation","enrollment":36},{"nctId":"NCT03539614","phase":"PHASE3","title":"Predicting Responses to PTSD Treatment With Iris and Cardiovascular Tests","status":"ACTIVE_NOT_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2018-06-04","conditions":"Posttraumatic Stress Disorder","enrollment":87},{"nctId":"NCT06629090","phase":"PHASE2","title":"Brain Blood Vessel Responses to Changes in Blood Flow: Younger Cohort","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2025-12-17","conditions":"Magnetic Resonance Imaging, Cerebrovascular Circulation","enrollment":36},{"nctId":"NCT04793685","phase":"PHASE2","title":"Prazosin for Alcohol Use Disorder With Withdrawal Symptoms","status":"RECRUITING","sponsor":"Yale University","startDate":"2021-07-01","conditions":"Alcohol Withdrawal","enrollment":150},{"nctId":"NCT03045016","phase":"PHASE2","title":"Efficacy of Prazosin in Preventing Post-traumatic Stress Disorder","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2017-04-21","conditions":"Acute Stress Disorder","enrollment":15},{"nctId":"NCT01437046","phase":"EARLY_PHASE1","title":"Doxazosin an a1 Antagonist for Alcohol Dependence","status":"COMPLETED","sponsor":"Brown University","startDate":"2011-11-01","conditions":"Alcohol Dependence, Anxiety","enrollment":41},{"nctId":"NCT05360953","phase":"PHASE2","title":"Treating Nightmares in Posttraumatic Stress Disorder With Clonidine and Doxazosin","status":"SUSPENDED","sponsor":"Charite University, Berlin, Germany","startDate":"2022-06-17","conditions":"Posttraumatic Stress Disorder","enrollment":53},{"nctId":"NCT04721353","phase":"PHASE4","title":"Reducing Cannabis Overuse With Prazosin","status":"COMPLETED","sponsor":"VA Puget Sound Health Care System","startDate":"2020-11-09","conditions":"Cannabis Dependence, Posttraumatic Stress Disorder, Cannabis Use Disorder","enrollment":11},{"nctId":"NCT03997864","phase":"PHASE4","title":"Administration of Prazosin to Prevent PTSD in Adult Women After Sexual Assault","status":"WITHDRAWN","sponsor":"University of Colorado, Denver","startDate":"2020-02-23","conditions":"Posttraumatic Stress Disorder","enrollment":0},{"nctId":"NCT06147622","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetic Profile of Prazosin and Cyproheptadine","status":"COMPLETED","sponsor":"Kinnov Therapeutics","startDate":"2024-04-23","conditions":"Alcohol Use Disorder","enrollment":12},{"nctId":"NCT02901977","phase":"PHASE4","title":"Doxazosin and Ramipril in Hypertension","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2011-03","conditions":"Hypertension","enrollment":71},{"nctId":"NCT06615440","phase":"","title":"Management and Outcome of Scorpion Sting in Children","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-11","conditions":"Scorpion Stings","enrollment":70},{"nctId":"NCT01379898","phase":"PHASE4","title":"Phenoxybenzamine Versus Doxazosin in PCC Patients","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2011-12","conditions":"Pheochromocytoma","enrollment":134},{"nctId":"NCT04967443","phase":"PHASE1","title":"Pivotal Bioequivalence Study to Qualify Manufacturing Site Transfer for Prazosin Hydrochloride Capsules","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-09-22","conditions":"Hypertension, Heart Failure","enrollment":72},{"nctId":"NCT02965027","phase":"PHASE4","title":"Prazosin for Post-Concussive Headaches","status":"COMPLETED","sponsor":"Seattle Institute for Biomedical and Clinical Research","startDate":"2016-11-29","conditions":"Post-Traumatic Headache","enrollment":89},{"nctId":"NCT02266329","phase":"PHASE1, PHASE2","title":"Chronic Postconcussive Headache: A Placebo-Controlled Treatment Trial of Prazosin","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2016-01-04","conditions":"Posttraumatic Headache, Combat Disorders, Post Concussion Syndrome","enrollment":89},{"nctId":"NCT03339258","phase":"PHASE2","title":"A Randomized Controlled Trial of Doxazosin for Nightmares, Sleep Disturbance, and Non-Nightmare Clinical Symptoms in PTSD","status":"ACTIVE_NOT_RECRUITING","sponsor":"San Francisco Veterans Affairs Medical Center","startDate":"2018-04-15","conditions":"Stress Disorders, Post-Traumatic","enrollment":80},{"nctId":"NCT00006294","phase":"","title":"Genetics of Hypertension Associated Treatments (GenHAT)","status":"COMPLETED","sponsor":"Donna Arnett, 257-5678","startDate":"1999-09","conditions":"Cardiovascular Diseases, Heart Diseases, Hypertension","enrollment":37939},{"nctId":"NCT04108104","phase":"PHASE2","title":"Clinical Outcome of a Patented Pharmaceutical Composition (KT-110) to Treat Alcohol Use Disorder While Avoiding Major Side Effects","status":"COMPLETED","sponsor":"Kinnov Therapeutics","startDate":"2019-11-30","conditions":"Alcohol Use Disorder","enrollment":154},{"nctId":"NCT06287905","phase":"PHASE4","title":"A Comparative Study of Using Scorpion Antivenom Versus Scorpion Antivenom and Prazosin","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2023-02-01","conditions":"Morality","enrollment":80},{"nctId":"NCT06282731","phase":"EARLY_PHASE1","title":"The Changes of Urine Growth Factors Level","status":"COMPLETED","sponsor":"En Chu Kong Hospital","startDate":"2013-05-31","conditions":"Benign Prostatic Hyperplasia","enrollment":74},{"nctId":"NCT03221751","phase":"PHASE4","title":"Prazosin and Cerebrospinal Fluid (CSF) Biomarkers in Mild Traumatic Brain Injury (mTBI)","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2016-12-01","conditions":"Dementia","enrollment":9},{"nctId":"NCT05189977","phase":"PHASE1","title":"A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-09-07","conditions":"Post-traumatic Stress Disorder (PTSD)","enrollment":34},{"nctId":"NCT01798992","phase":"PHASE4","title":"Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2000-09","conditions":"Idiopathic Dilated Cardiomyopathy","enrollment":56},{"nctId":"NCT03176693","phase":"PHASE3","title":"Preoperative Alpha Blockade for Pheochromocytoma","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2017-05-05","conditions":"Pheochromocytoma, Paraganglioma","enrollment":39},{"nctId":"NCT04280965","phase":"EARLY_PHASE1","title":"Quetiapine Augmentation of PE Therapy for the Treatment of Co-occurring PTSD and Mild Traumatic Brain Injury","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2019-02-01","conditions":"Post Traumatic Stress Disorder","enrollment":28},{"nctId":"NCT02616094","phase":"NA","title":"Multimodal Neuroimaging of Stress and Reward Cues to Assess Alcoholism Risk and Relapse","status":"COMPLETED","sponsor":"Yale University","startDate":"2015-11","conditions":"Alcohol Dependence","enrollment":224},{"nctId":"NCT04365257","phase":"PHASE2","title":"Prazosin to Prevent COVID-19 (PREVENT-COVID Trial)","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2020-05-13","conditions":"COVID-19","enrollment":5},{"nctId":"NCT03710642","phase":"PHASE2","title":"Prazosin for Agitation in Alzheimer's Disease","status":"COMPLETED","sponsor":"Alzheimer's Disease Cooperative Study (ADCS)","startDate":"2018-10-23","conditions":"Alzheimer's Disease, Disruptive Behavior","enrollment":35},{"nctId":"NCT02226367","phase":"NA","title":"Prazosin Augmentation of Outpatient Treatment of Alcohol Use Disorders in Active Duty Soldiers With and Without PTSD","status":"COMPLETED","sponsor":"Seattle Institute for Biomedical and Clinical Research","startDate":"2015-01","conditions":"Alcohol Use Disorders, Stress Disorders, Posttraumatic, Combat Disorders","enrollment":158},{"nctId":"NCT03894345","phase":"PHASE1","title":"Prazosin Use in Adults With Anxiety Disorders","status":"SUSPENDED","sponsor":"University of Manitoba","startDate":"2019-05-24","conditions":"Anxiety, Anxiety Disorders","enrollment":20},{"nctId":"NCT03398252","phase":"PHASE1","title":"Targeting Stress-Induced Alcohol Relapse Risk With Doxazosin XL","status":"WITHDRAWN","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2022-05-12","conditions":"Alcohol Use Disorder","enrollment":0},{"nctId":"NCT02308202","phase":"PHASE1","title":"DOXAZOSIN FOR PTSD","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2012-01","conditions":"PTSD","enrollment":30},{"nctId":"NCT02538744","phase":"PHASE1","title":"Complementary Combination Therapy for Cocaine Dependence","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2015-08","conditions":"Cocaine Dependence","enrollment":45},{"nctId":"NCT04320589","phase":"PHASE2","title":"the Effect of Dexmedetomidine and Magnesium Sulfate in Open Resection of Pheochromocytoma","status":"COMPLETED","sponsor":"National Cancer Institute, Egypt","startDate":"2019-06-30","conditions":"Pheochromocytoma","enrollment":30},{"nctId":"NCT02655354","phase":"NA","title":"A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-10","conditions":"Posttraumatic Stress Disorder, Depression, Alcohol-Related Disorders","enrollment":635},{"nctId":"NCT01030874","phase":"NA","title":"Orthostatic Hypotension Treatment on Rehab Unit","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2011-10","conditions":"Orthostatic Hypotension, Falls","enrollment":356},{"nctId":"NCT04557072","phase":"","title":"Selective Versus Nonselective Alpha-blockade Prior to Pheochromocytoma Resection - Systematic Review and Meta-analysis","status":"COMPLETED","sponsor":"Jagiellonian University","startDate":"2020-08-01","conditions":"Pheochromocytoma","enrollment":1344},{"nctId":"NCT02500602","phase":"PHASE2","title":"CAP: Doxazosin in the Treatment of Co-Occurring PTSD and Alcohol Use Disorders","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2016-06-01","conditions":"Posttraumatic Stress Disorder, Alcohol Use Disorders","enrollment":144},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT02989493","phase":"PHASE2","title":"Testing Doxazosin to Treat Stress Mechanisms in Alcoholism","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2017-04-12","conditions":"Alcoholism","enrollment":61},{"nctId":"NCT01389609","phase":"PHASE1","title":"Bioequivalence Study of Doxazosin 4 Mg Orally-Disintegrating Tablet With Or Without Water To Doxazosin 4 Mg Japanese Marketed Immediate Release Tablet Under Fasted Condition","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2011-07","conditions":"Hypertension","enrollment":24},{"nctId":"NCT02322047","phase":"PHASE2","title":"Prazosin and Naltrexone (PaN) Study for Veterans With Alcohol Use Disorders","status":"COMPLETED","sponsor":"Seattle Institute for Biomedical and Clinical Research","startDate":"2015-03-03","conditions":"Alcohol Use Disorder, Posttraumatic Stress Disorder (PTSD)","enrollment":31},{"nctId":"NCT01518972","phase":"PHASE2","title":"Prazosin for Alcohol Dependence and Posttraumatic Stress Disorder","status":"COMPLETED","sponsor":"Seattle Institute for Biomedical and Clinical Research","startDate":"2009-09","conditions":"Alcohol Abuse, Posttraumatic Stress Disorder","enrollment":30},{"nctId":"NCT00535925","phase":"PHASE4","title":"Nephropathy In Type 2 Diabetes and Cardio-renal Events","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2005-10","conditions":"Diabetic Nephropathy","enrollment":850},{"nctId":"NCT00585780","phase":"PHASE1, PHASE2","title":"Prazosin to Reduce Stress-Induced Alcohol/Drug Craving and Relapse","status":"COMPLETED","sponsor":"Yale University","startDate":"2009-09","conditions":"Alcohol Dependence","enrollment":100},{"nctId":"NCT00762710","phase":"PHASE2","title":"Study of the Medication Prazosin for Alcohol Dependence","status":"COMPLETED","sponsor":"Seattle Institute for Biomedical and Clinical Research","startDate":"2008-01","conditions":"Alcoholism","enrollment":92},{"nctId":"NCT04371757","phase":"NA","title":"Influence of the Autonomic Nervous System in Response to Exercise in Hypertensive Individuals","status":"UNKNOWN","sponsor":"Instituto de Cardiologia do Rio Grande do Sul","startDate":"2020-04-30","conditions":"Autonomic Nervous System, Hypertension","enrollment":39},{"nctId":"NCT00744055","phase":"PHASE3","title":"Prazosin for Treatment of Patients With Alcohol Dependence (AD) and Post Traumatic Stress Disorder (PTSD).","status":"COMPLETED","sponsor":"Yale University","startDate":"2009-01","conditions":"Alcohol Dependence, Stress Disorders, Post-Traumatic","enrollment":96},{"nctId":"NCT02193256","phase":"EARLY_PHASE1","title":"Varenicline + Prazosin for Heavy Drinking Smokers","status":"COMPLETED","sponsor":"Yale University","startDate":"2014-07","conditions":"Cigarette Smoking, Alcohol Use Disorders","enrollment":5},{"nctId":"NCT01953432","phase":"PHASE2","title":"Pharmacogenetic Trial of Doxazosin for Treatment of Cocaine Abuse","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2014-04-01","conditions":"Cocaine Dependence","enrollment":43},{"nctId":"NCT00922506","phase":"PHASE4","title":"Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH)","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2009-05","conditions":"Overactive Bladder, Benign Prostatic Hyperplasia","enrollment":83},{"nctId":"NCT00880997","phase":"PHASE1","title":"The Efficacy of Doxazosin for Cocaine Users","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2009-09","conditions":"Cocaine Dependence","enrollment":35},{"nctId":"NCT03416569","phase":"NA","title":"Effects of Prazosin on the Attention-Enhancing Effects of Nicotine","status":"WITHDRAWN","sponsor":"University of Maryland, Baltimore","startDate":"2018-03","conditions":"no Condition, Basic Science","enrollment":0},{"nctId":"NCT01145183","phase":"PHASE2","title":"Pharmacogenetics of Doxazosin for Cocaine Dependence","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2010-03","conditions":"Cocaine Dependence","enrollment":96},{"nctId":"NCT02382848","phase":"NA","title":"Effectiveness of Prazosin in Bulimic Patients Experiencing Nightmares Due to PTSD","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2015-07","conditions":"Stress Disorders, Post-Traumatic, Bulimia Nervosa","enrollment":9},{"nctId":"NCT02431936","phase":"PHASE2","title":"Effectiveness of Prazosin on the Urinary Sodium Excretion Response to Mental Stress","status":"COMPLETED","sponsor":"Augusta University","startDate":"2015-04","conditions":"Hypertension, Stress, Psychological, Blood Pressure","enrollment":50},{"nctId":"NCT01999530","phase":"PHASE1","title":"The Effects of Prazosin on Dopamine in Healthy Humans: A PET Pilot Study","status":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","startDate":"2013-11","conditions":"Healthy","enrollment":20},{"nctId":"NCT02966340","phase":"PHASE1, PHASE2","title":"Repurposing alpha1 Noradrenergic Antagonists for Alcoholism Treatment","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2016-11-01","conditions":"Alcoholism","enrollment":70},{"nctId":"NCT00487032","phase":"PHASE4","title":"Differential Adrenoreceptor Mediated Tachyphylaxis and Upregulation","status":"COMPLETED","sponsor":"Brian J Lipworth","startDate":"2008-05","conditions":"Allergic Rhinitis, Tachyphylaxis, Rhinitis Medicamentosa","enrollment":19},{"nctId":"NCT01923129","phase":"NA","title":"Optimal Duration of Indwelling Urinary Catheter Following Pelvic Surgery","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2012-11-30","conditions":"Urinary Retention","enrollment":142},{"nctId":"NCT01386177","phase":"PHASE1","title":"Pharmacological Interaction Between Doxazosin and Methylenedioxymethamphetamine (MDMA)","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2011-07","conditions":"Mood Disorder, Substance-Related Disorders, Amphetamine-Related Disorders","enrollment":16},{"nctId":"NCT00021814","phase":"PHASE3","title":"Medical Therapy of Prostatic Symptoms","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"1995-12","conditions":"Prostatic Hyperplasia, Prostatic Hypertrophy, Benign","enrollment":3407},{"nctId":"NCT02199652","phase":"PHASE4","title":"Reducing Suicidal Ideation Through Treatment of Nightmares-Post Traumatic Stress Disorder (PTSD)","status":"COMPLETED","sponsor":"Augusta University","startDate":"2014-03","conditions":"Post Traumatic Stress Disorder, Suicidal Ideation, Nightmares","enrollment":20},{"nctId":"NCT00240227","phase":"NA","title":"Prazosin for ETOH or Cocaine Craving","status":"TERMINATED","sponsor":"US Department of Veterans Affairs","startDate":"2004-04","conditions":"Alcoholism, Cocaine Dependence","enrollment":8},{"nctId":"NCT00741585","phase":"PHASE4","title":"Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment","status":"COMPLETED","sponsor":"University of Vigo","startDate":"2008-09-01","conditions":"Essential Hypertension, Cardiovascular Disease, Stroke","enrollment":21983},{"nctId":"NCT03010995","phase":"PHASE1","title":"The Acute Cardiovascular Effects of Nicotine in E-cigarettes (ACE) Study","status":"WITHDRAWN","sponsor":"University of Louisville","startDate":"2018-03-13","conditions":"Cigarette Smoking Toxicity, Nicotine, Acute Cardiovascular Disease","enrollment":0},{"nctId":"NCT00202449","phase":"NA","title":"Prazosin vs Paroxetine in Combat Stress-Related Post-Traumatic Stress Disorder (PTSD) Nightmares & Sleep Disturbance","status":"TERMINATED","sponsor":"Seattle Institute for Biomedical and Clinical Research","startDate":"2004-07","conditions":"Stress Disorders, Post-Traumatic, Sleep Disorders","enrollment":59},{"nctId":"NCT00183430","phase":"NA","title":"Prazosin for Treating Noncombat Trauma Post-Traumatic Stress Disorder","status":"TERMINATED","sponsor":"Seattle Institute for Biomedical and Clinical Research","startDate":"2003-10","conditions":"Post-Traumatic Stress Disorder, Sleep Initiation and Maintenance Disorders","enrollment":20},{"nctId":"NCT00990106","phase":"NA","title":"Augmentation Trial of Prazosin for Post-Traumatic Stress Disorder (PTSD)","status":"COMPLETED","sponsor":"Seattle Institute for Biomedical and Clinical Research","startDate":"2009-09","conditions":"Stress Disorders, Post-Traumatic, Combat Disorders, Sleep Disorders","enrollment":67},{"nctId":"NCT00532493","phase":"PHASE3","title":"Cooperative Studies Program #563 - Prazosin and Combat Trauma PTSD","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2010-01-06","conditions":"PTSD, Sleep Disorders","enrollment":304},{"nctId":"NCT01862497","phase":"","title":"Mechanisms of Increased Ambulatory Blood Pressure in Patients With Intradialytic Hypertension","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2013-01","conditions":"Intradialytic Hypertension","enrollment":76},{"nctId":"NCT01730846","phase":"PHASE2","title":"Does Doxazosin Attenuate Stress-induced Smoking and Improve Clinical Outcomes?","status":"COMPLETED","sponsor":"Yale University","startDate":"2013-02","conditions":"Smoking","enrollment":35},{"nctId":"NCT02539810","phase":"PHASE4","title":"Renal Artery Stenting in Patients With Documented Resistant Hypertension and Atherosclerotic Renal Artery Stenosis (ANDORRA)","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-09","conditions":"Hypertension, Hypertension Resistant to Conventional Therapy, Angiographically Proven Grade III Unilateral or Bilateral Atherosclerotic Renal Artery Stenosis (ARAS) Greater Than or Equal to 60 Percent","enrollment":4},{"nctId":"NCT01916941","phase":"NA","title":"Neural Mechanisms of Change During the Treatment of Alcohol Use Disorders With Prazosin","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2013-09","conditions":"Alcohol Use Disorder","enrollment":36},{"nctId":"NCT00223717","phase":"PHASE1","title":"Treatment of Supine Hypertension in Autonomic Failure","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2001-01","conditions":"Hypertension","enrollment":152},{"nctId":"NCT01323998","phase":"","title":"Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-04","conditions":"Prostatic Hyperplasia","enrollment":35032},{"nctId":"NCT01332487","phase":"","title":"Evaluating the Impact of Early Versus Delayed 5 Alpha Reductase Inhibitor Treatment on the Risk of Emergent Surgery in Men With Benign Prostatic Hyperplasia","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08","conditions":"Prostatic Hyperplasia","enrollment":4068},{"nctId":"NCT01637584","phase":"NA","title":"Neurobiology of Sleep and Sleep Treatment Response in Returning Veterans","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2010-04","conditions":"Non PTSD, PTSD","enrollment":40},{"nctId":"NCT01542372","phase":"PHASE4","title":"Two Stepped Care Models for Posttraumatic Stress Disorder (PTSD) Among Cambodian Refugees With PTSD","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2012-04","conditions":"Posttraumatic Stress Disorder (PTSD)","enrollment":114},{"nctId":"NCT00175682","phase":"NA","title":"Prazosin Vibrostimulation Autonomic Dysreflexia and Spinal Cord Injury Study","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2004-12","conditions":"Autonomic Dysreflexia","enrollment":7},{"nctId":"NCT01178138","phase":"PHASE2","title":"Monoamine Antagonist Therapies for Methamphetamine Abuse Prazosin","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2009-12","conditions":"Continuous Methamphetamine Abuse","enrollment":24},{"nctId":"NCT00393874","phase":"NA","title":"Efficacy of Sleep Interventions for Posttraumatic Stress Disorder (PTSD)","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2006-10","conditions":"Anxiety Disorders, Mood Disorders, Insomnia","enrollment":50},{"nctId":"NCT01959022","phase":"PHASE4","title":"A Pilot Study to Assess the Effects of Doxazosin on Polysomnography in PTSD","status":"COMPLETED","sponsor":"San Francisco Veterans Affairs Medical Center","startDate":"2013-10","conditions":"Stress Disorders, Post-Traumatic","enrollment":15},{"nctId":"NCT02785393","phase":"PHASE1","title":"DOX as a Potential Treatment for Methamphetamine Dependence","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2011-03","conditions":"Substance-Related Disorders","enrollment":11},{"nctId":"NCT00000542","phase":"PHASE3","title":"Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1993-08","conditions":"Cardiovascular Diseases, Coronary Disease, Diabetes Mellitus","enrollment":""},{"nctId":"NCT02563405","phase":"PHASE2, PHASE3","title":"The Effects of Doxazosin and Nifedipine on Blood Pressure Variability and Uric Acid in Plasma in Hypertensive Patients","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Harbin Medical University","startDate":"2015-09","conditions":"Hypertension","enrollment":30},{"nctId":"NCT02384369","phase":"PHASE2","title":"Trial of Oral SNC-102 in Subjects With Combat-Related Posttraumatic Stress Disorder","status":"WITHDRAWN","sponsor":"Synchroneuron Inc.","startDate":"2016-06","conditions":"Post-Traumatic Stress Disorders, Posttraumatic Stress Disorders, Stress Disorders, Post-Traumatic","enrollment":0},{"nctId":"NCT00000522","phase":"PHASE2","title":"Treatment of Mild Hypertension Study (TOMHS)","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"1985-08","conditions":"Cardiovascular Diseases, Heart Diseases, Hypertension","enrollment":""},{"nctId":"NCT01642433","phase":"PHASE2","title":"Prazosin for Smoking Cessation","status":"TERMINATED","sponsor":"Centre for Addiction and Mental Health","startDate":"2012-07","conditions":"Nicotine Dependence","enrollment":1},{"nctId":"NCT02369081","phase":"PHASE4","title":"Optimum Treatment for Drug-Resistant Hypertension","status":"UNKNOWN","sponsor":"University of Cambridge","startDate":"2009-05","conditions":"Hypertension, Resistant to Conventional Therapy","enrollment":348},{"nctId":"NCT00141596","phase":"NA","title":"Extracellular Fluid in Resistant Hypertension","status":"TERMINATED","sponsor":"St George's, University of London","startDate":"2003-07","conditions":"Hypertension","enrollment":32},{"nctId":"NCT01126099","phase":"NA","title":"Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease","status":"COMPLETED","sponsor":"Seattle Institute for Biomedical and Clinical Research","startDate":"2010-03","conditions":"Alzheimer's Disease","enrollment":20},{"nctId":"NCT02266537","phase":"PHASE1","title":"Study to Assess the Influence of Three Different α-antagonists and Placebo on the Extent of Weekly Phenylephrine-induced Mydriasis at Three Different Concentrations of Phenylephrine in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-11","conditions":"Healthy","enrollment":97},{"nctId":"NCT01678313","phase":"PHASE2","title":"Cyclooxygenase-2 (COX-2) Inhibitor Reduces Serum Prostatic Specific Antigen (PSA) Levels","status":"COMPLETED","sponsor":"Buddhist Tzu Chi General Hospital","startDate":"2012-08","conditions":"Benign Prostatic Hyperplasia","enrollment":140},{"nctId":"NCT01661621","phase":"PHASE4","title":"Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1","status":"COMPLETED","sponsor":"Buddhist Tzu Chi General Hospital","startDate":"2012-08","conditions":"Bladder Outlet Obstruction","enrollment":395},{"nctId":"NCT00890643","phase":"NA","title":"Effect of Prazosin on Neurophysiology and Cognition in Post-Traumatic Stress Disorder (PTSD)","status":"WITHDRAWN","sponsor":"US Department of Veterans Affairs","startDate":"2009-12","conditions":"Posttraumatic Stress Disorder","enrollment":0},{"nctId":"NCT00687388","phase":"PHASE4","title":"The Clinical Efficacy of Non-steroidal Anti-inflammation Drugs in Patients With Benign Prostatic Hyperplasia","status":"WITHDRAWN","sponsor":"Samsung Medical Center","startDate":"2008-05","conditions":"Benign Prostatic Hyperplasia","enrollment":0}],"_emaApprovals":[{"date":"","name":"Prazosin HCl","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[{"role":"Manufacturer","site":"Direct_Rx","location":"","operator":"Direct_Rx"}],"molecularData":{"oral":true,"chemblId":"CHEMBL1558","moleculeType":"Small molecule","molecularWeight":"419.87"},"administration":{"route":"Oral","formulations":[{"form":"CAPSULE","route":"ORAL","tradeName":"PRAZOSIN HYDROCHLORIDE"},{"form":"CAPSULE","route":"ORAL","tradeName":"Prazosin HCL"},{"form":"CAPSULE","route":"ORAL","tradeName":"Prazosin Hydrochloride"},{"form":"CAPSULE","route":"ORAL","tradeName":"Prazosin hydrochloride"},{"form":"CAPSULE","route":"ORAL","tradeName":"prazosin hydrochloride"},{"form":"CAPSULE","route":"ORAL","tradeName":"Minipress"},{"form":"CAPSULE","route":"ORAL","tradeName":"Prazosin Hydrochloride"},{"form":"CAPSULE","route":"ORAL","tradeName":"Prazosin"},{"form":"CAPSULE","route":"ORAL","tradeName":"Prazosin Hydrochloride"}]},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"NUI":"N0000147986","MMSL":"2426","NDDF":"000635","UNII":"XM03YJ541D","VUID":"4019901","CHEBI":"CHEBI:8364","VANDF":"4018850","INN_ID":"2593","RXNORM":"203210","UMLSCUI":"C0032912","chemblId":"CHEMBL1558","ChEMBL_ID":"CHEMBL2","KEGG_DRUG":"D00609","DRUGBANK_ID":"DB00457","PDB_CHEM_ID":" XRA","PUBCHEM_CID":"4893","SNOMEDCT_US":"387283005","IUPHAR_LIGAND_ID":"503","SECONDARY_CAS_RN":"19237-84-4","MESH_DESCRIPTOR_UI":"D011224"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1976-present","_source":"FDA label","companyName":"Direct_Rx","relationship":"Originator"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"2.0 hours","clearance":"4.7 mL/min/kg","bioavailability":"68.0%","fractionUnbound":"0.06%","volumeOfDistribution":"0.73 L/kg"},"publicationCount":28,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"C02CA01","allCodes":["C02CA01","C02LE01"]},"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"small molecule","firstApprovalDate":"1976","enrichmentLevel":3,"visitCount":3,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"13980.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:54:13.010287+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}